I just wanted to highlight the following observation;
'Off Label Drug Use may highlight conditions which warrant supplementary clinical trials'.
Off Label use could be cost effective in opening the doorway to study the effect of Trofinetide on a range of neurodevelopmental and neurodegenerative disorders.
Reasons for consideration, page-99
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.46 |
Change
0.010(0.07%) |
Mkt cap ! $1.841B | |||
| Open | High | Low | Value | Volume |
| $14.50 | $14.59 | $14.34 | $1.758M | 121.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 1003 | $14.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.47 | 301 | 10 |
View Market Depth
| Last trade - 15.17pm 31/01/2025 (20 minute delay) ? |
| NEU (ASX) Chart |